CAL
UTHR icon

Capital Advisors Ltd’s United Therapeutics UTHR Stock Holding History

Capital Advisors Ltd’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7K Hold
13
– – ﹤0.01% 926
2026
Q1 		$8K Hold
13
– – ﹤0.01% 882
2025
Q4 		$6K Hold
13
– – ﹤0.01% 921
2025
Q3 		$5K Buy
13
+11
+550% +$3.7K ﹤0.01% 937
2025
Q2 		$1K Hold
2
– – ﹤0.01% 1285
2025
Q1 		$1K Hold
2
– – ﹤0.01% 1282
2024
Q4 		$1K Hold
2
– – ﹤0.01% 1318
2024
Q3 		$1K Hold
2
– – ﹤0.01% 1308
2024
Q2 		$1K Sell
2
-1
-33% -$265 ﹤0.01% 1309
2024
Q1 		$1K Buy
3
+1
+50% +$226 ﹤0.01% 1287
2023
Q4 		$0 Hold
2
– – ﹤0.01% 1499
2023
Q3 		$0 Hold
2
– – ﹤0.01% 1490
2023
Q2 		$0 Sell
2
-2
-50% -$443 ﹤0.01% 1550
2023
Q1 		$1K Sell
4
-7
-64% -$1.73K ﹤0.01% 1126
2022
Q4 		$3K Buy
11
+9
+450% +$2.27K ﹤0.01% 805
2022
Q3 		$0 Buy
+2
New +$447 ﹤0.01% 1542

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Capital Advisors Ltd's UTHR Position: Q2 2026 in Review

Capital Advisors Ltd held its United Therapeutics (UTHR) position steady in Q2 2026 at 13 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #926.

Capital Advisors Ltd first reported a position in UTHR in Q3 2022 and has held it in 16 quarters since. The position peaked at $8K in Q1 2026. 875 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Capital Advisors Ltd held 13 shares of United Therapeutics worth $7K as of Q2 2026.
  • Capital Advisors Ltd left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up ﹤0.01% of Capital Advisors Ltd's portfolio in Q2 2026, its #926 holding.
  • Capital Advisors Ltd first reported a position in United Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • Capital Advisors Ltd's United Therapeutics position peaked at $8K in Q1 2026.
  • 875 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Capital Advisors Ltd's 13F filing for Q2 2026, filed 16 Jul 2026.